questionsmedicales.fr
Actions chimiques et utilisations
Actions pharmacologiques
Utilisations thérapeutiques
Antinéoplasiques
Agonistes myélo-ablatifs
Agonistes myélo-ablatifs : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Biopsie de la moelle osseuse
Tests sanguins
Imagerie médicale
Fonction hépatique
Marqueurs tumoraux
Anomalies hématologiques
Évaluation de la moelle osseuse
Tests de fonction hématologique
Symptômes
5
Nausées
Immunosuppression
Prévention
5
Effets secondaires
Suivi médical
Soutien psychologique
Anxiété
Traitements
5
Chimiothérapie
Greffe de moelle osseuse
Greffe de cellules souches
Préparation myélo-ablatif
Busulfan
Cyclophosphamide
Surveillance médicale
Complications
Gestion de la douleur
Soutien psychologique
Complications
5
Saignement
Thrombocytopénie
Anémie
Transfusions sanguines
Troubles hématologiques
Cancer secondaire
Facteurs de risque
5
Cancers hématologiques
Antécédents médicaux
Mutations génétiques
Prédisposition
Radiothérapie
Chimiothérapie
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Agonistes myélo-ablatifs : Questions médicales les plus fréquentes",
"headline": "Agonistes myélo-ablatifs : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Agonistes myélo-ablatifs : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-12",
"dateModified": "2026-04-03",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Agonistes myélo-ablatifs"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Antinéoplasiques",
"url": "https://questionsmedicales.fr/mesh/D000970",
"about": {
"@type": "MedicalCondition",
"name": "Antinéoplasiques",
"code": {
"@type": "MedicalCode",
"code": "D000970",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.954.248"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Agonistes myélo-ablatifs",
"alternateName": "Myeloablative Agonists",
"code": {
"@type": "MedicalCode",
"code": "D019653",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Elizabeth J Shpall",
"url": "https://questionsmedicales.fr/author/Elizabeth%20J%20Shpall",
"affiliation": {
"@type": "Organization",
"name": "Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas."
}
},
{
"@type": "Person",
"name": "Richard E Champlin",
"url": "https://questionsmedicales.fr/author/Richard%20E%20Champlin",
"affiliation": {
"@type": "Organization",
"name": "Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas."
}
},
{
"@type": "Person",
"name": "Qaiser Bashir",
"url": "https://questionsmedicales.fr/author/Qaiser%20Bashir",
"affiliation": {
"@type": "Organization",
"name": "Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas."
}
},
{
"@type": "Person",
"name": "Amin M Alousi",
"url": "https://questionsmedicales.fr/author/Amin%20M%20Alousi",
"affiliation": {
"@type": "Organization",
"name": "Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas."
}
},
{
"@type": "Person",
"name": "Chitra Hosing",
"url": "https://questionsmedicales.fr/author/Chitra%20Hosing",
"affiliation": {
"@type": "Organization",
"name": "Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Perceived Risk of Binge Drinking among Older Alcohol Users: Associations with Alcohol Use Frequency, Binge Drinking, Alcohol Use Disorder, and Alcohol Treatment Use.",
"datePublished": "2024-08-16",
"url": "https://questionsmedicales.fr/article/39200690",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijerph21081081"
}
},
{
"@type": "ScholarlyArticle",
"name": "Relationship between self-stigma about alcohol dependence and severity of alcohol drinking and craving.",
"datePublished": "2023-11-22",
"url": "https://questionsmedicales.fr/article/37993282",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1136/bmjment-2023-300852"
}
},
{
"@type": "ScholarlyArticle",
"name": "Characteristic associated with alcohol drinking in early pregnancy: a cross sectional study.",
"datePublished": "2023-07-05",
"url": "https://questionsmedicales.fr/article/37407640",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-023-38055-3"
}
},
{
"@type": "ScholarlyArticle",
"name": "Alcohol drinking, smoking, and cutaneous melanoma risk: Mendelian randomization analysis.",
"datePublished": "2023-12-04",
"url": "https://questionsmedicales.fr/article/38052122",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.gaceta.2023.102351"
}
},
{
"@type": "ScholarlyArticle",
"name": "Cask wine: Describing drinking patterns associated with Australia's cheapest alcohol.",
"datePublished": "2023-05-24",
"url": "https://questionsmedicales.fr/article/37224066",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/dar.13684"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Actions chimiques et utilisations",
"item": "https://questionsmedicales.fr/mesh/D020164"
},
{
"@type": "ListItem",
"position": 3,
"name": "Actions pharmacologiques",
"item": "https://questionsmedicales.fr/mesh/D020228"
},
{
"@type": "ListItem",
"position": 4,
"name": "Utilisations thérapeutiques",
"item": "https://questionsmedicales.fr/mesh/D045506"
},
{
"@type": "ListItem",
"position": 5,
"name": "Antinéoplasiques",
"item": "https://questionsmedicales.fr/mesh/D000970"
},
{
"@type": "ListItem",
"position": 6,
"name": "Agonistes myélo-ablatifs",
"item": "https://questionsmedicales.fr/mesh/D019653"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Agonistes myélo-ablatifs - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Agonistes myélo-ablatifs",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-05-15",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Agonistes myélo-ablatifs",
"description": "Comment diagnostiquer une nécessité d'agonistes myélo-ablatifs ?\nQuels examens sont nécessaires avant traitement ?\nQuels marqueurs indiquent un traitement myélo-ablatif ?\nComment évaluer l'état de la moelle osseuse ?\nQuels symptômes justifient un traitement myélo-ablatif ?",
"url": "https://questionsmedicales.fr/mesh/D019653?mesh_terms=Alcohol+Drinking#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Agonistes myélo-ablatifs",
"description": "Quels sont les symptômes d'une moelle osseuse affectée ?\nComment se manifeste l'anémie liée à la myélo-ablation ?\nQuels signes indiquent une infection après traitement ?\nQuels symptômes peuvent survenir après une myélo-ablation ?\nComment reconnaître une hémorragie liée à la myélo-ablation ?",
"url": "https://questionsmedicales.fr/mesh/D019653?mesh_terms=Alcohol+Drinking#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Agonistes myélo-ablatifs",
"description": "Comment prévenir les complications après myélo-ablation ?\nQuelles mesures prendre pour éviter les infections ?\nComment gérer les effets secondaires des agonistes ?\nQuels conseils nutritionnels sont recommandés ?\nComment le soutien psychologique aide-t-il ?",
"url": "https://questionsmedicales.fr/mesh/D019653?mesh_terms=Alcohol+Drinking#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Agonistes myélo-ablatifs",
"description": "Quels traitements sont associés aux agonistes myélo-ablatifs ?\nComment se déroule une greffe après myélo-ablation ?\nQuels médicaments sont utilisés comme agonistes myélo-ablatifs ?\nQuelle est l'importance de la surveillance post-traitement ?\nQuels soins de soutien sont nécessaires après traitement ?",
"url": "https://questionsmedicales.fr/mesh/D019653?mesh_terms=Alcohol+Drinking#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Agonistes myélo-ablatifs",
"description": "Quelles sont les complications possibles des agonistes myélo-ablatifs ?\nComment reconnaître une infection post-myélo-ablation ?\nQuels sont les risques de saignement après traitement ?\nComment gérer une anémie post-myélo-ablation ?\nQuelles sont les conséquences à long terme des agonistes ?",
"url": "https://questionsmedicales.fr/mesh/D019653?mesh_terms=Alcohol+Drinking#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Agonistes myélo-ablatifs",
"description": "Quels facteurs augmentent le besoin d'agonistes myélo-ablatifs ?\nComment l'âge influence-t-il le traitement ?\nQuels facteurs génétiques sont impliqués ?\nComment le mode de vie affecte-t-il le risque ?\nQuels antécédents médicaux sont des facteurs de risque ?",
"url": "https://questionsmedicales.fr/mesh/D019653?mesh_terms=Alcohol+Drinking#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une nécessité d'agonistes myélo-ablatifs ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des tests sanguins, biopsies de moelle osseuse et évaluation clinique."
}
},
{
"@type": "Question",
"name": "Quels examens sont nécessaires avant traitement ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des examens d'imagerie, des analyses sanguines et une évaluation de la fonction hépatique sont requis."
}
},
{
"@type": "Question",
"name": "Quels marqueurs indiquent un traitement myélo-ablatif ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des marqueurs tumoraux spécifiques et des anomalies hématologiques peuvent indiquer ce besoin."
}
},
{
"@type": "Question",
"name": "Comment évaluer l'état de la moelle osseuse ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une biopsie de moelle osseuse et des tests de fonction hématologique sont utilisés pour l'évaluation."
}
},
{
"@type": "Question",
"name": "Quels symptômes justifient un traitement myélo-ablatif ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes tels que l'anémie sévère, les infections récurrentes ou des hémorragies inexpliquées peuvent justifier ce traitement."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une moelle osseuse affectée ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent fatigue, infections fréquentes, ecchymoses et saignements anormaux."
}
},
{
"@type": "Question",
"name": "Comment se manifeste l'anémie liée à la myélo-ablation ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'anémie se manifeste par une fatigue accrue, des palpitations et une pâleur de la peau."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une infection après traitement ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes tels que fièvre, frissons, et malaise général peuvent indiquer une infection."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent survenir après une myélo-ablation ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme des nausées, vomissements, et une immunosuppression peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment reconnaître une hémorragie liée à la myélo-ablation ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des saignements inhabituels, des ecchymoses et des saignements de nez fréquents sont des signes."
}
},
{
"@type": "Question",
"name": "Comment prévenir les complications après myélo-ablation ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention inclut des soins d'hygiène rigoureux et des vaccinations appropriées."
}
},
{
"@type": "Question",
"name": "Quelles mesures prendre pour éviter les infections ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter les foules, se laver les mains fréquemment et porter un masque en cas de besoin."
}
},
{
"@type": "Question",
"name": "Comment gérer les effets secondaires des agonistes ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion des effets secondaires passe par des médicaments symptomatiques et un suivi régulier."
}
},
{
"@type": "Question",
"name": "Quels conseils nutritionnels sont recommandés ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée, riche en protéines et en vitamines, est recommandée pour la récupération."
}
},
{
"@type": "Question",
"name": "Comment le soutien psychologique aide-t-il ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le soutien psychologique aide à gérer l'anxiété et le stress liés au traitement et à la maladie."
}
},
{
"@type": "Question",
"name": "Quels traitements sont associés aux agonistes myélo-ablatifs ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent la chimiothérapie, la radiothérapie et les greffes de moelle osseuse."
}
},
{
"@type": "Question",
"name": "Comment se déroule une greffe après myélo-ablation ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La greffe implique la transplantation de cellules souches après une préparation myélo-ablatif."
}
},
{
"@type": "Question",
"name": "Quels médicaments sont utilisés comme agonistes myélo-ablatifs ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des agents comme le busulfan et la cyclophosphamide sont couramment utilisés."
}
},
{
"@type": "Question",
"name": "Quelle est l'importance de la surveillance post-traitement ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "La surveillance est cruciale pour détecter les complications et ajuster le traitement si nécessaire."
}
},
{
"@type": "Question",
"name": "Quels soins de soutien sont nécessaires après traitement ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des soins de soutien incluent la gestion de la douleur, la nutrition et le soutien psychologique."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles des agonistes myélo-ablatifs ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent l'infection, l'anémie, et des troubles de la coagulation."
}
},
{
"@type": "Question",
"name": "Comment reconnaître une infection post-myélo-ablation ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme fièvre, frissons et fatigue intense peuvent indiquer une infection."
}
},
{
"@type": "Question",
"name": "Quels sont les risques de saignement après traitement ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les risques de saignement augmentent en raison de la thrombocytopénie induite par le traitement."
}
},
{
"@type": "Question",
"name": "Comment gérer une anémie post-myélo-ablation ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion de l'anémie peut nécessiter des transfusions sanguines et des suppléments de fer."
}
},
{
"@type": "Question",
"name": "Quelles sont les conséquences à long terme des agonistes ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les conséquences peuvent inclure des troubles hématologiques chroniques et des risques de cancer secondaire."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le besoin d'agonistes myélo-ablatifs ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des antécédents de cancers hématologiques et des traitements antérieurs augmentent ce besoin."
}
},
{
"@type": "Question",
"name": "Comment l'âge influence-t-il le traitement ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les patients plus âgés peuvent avoir un risque accru de complications et une tolérance réduite."
}
},
{
"@type": "Question",
"name": "Quels facteurs génétiques sont impliqués ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des mutations génétiques spécifiques peuvent prédisposer à des maladies nécessitant une myélo-ablation."
}
},
{
"@type": "Question",
"name": "Comment le mode de vie affecte-t-il le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie malsain, comme le tabagisme, peut augmenter le risque de cancers hématologiques."
}
},
{
"@type": "Question",
"name": "Quels antécédents médicaux sont des facteurs de risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des antécédents de radiothérapie ou de chimiothérapie augmentent le risque de complications."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 03/04/2026
Contenu vérifié selon les dernières recommandations médicales
4 publications dans cette catégorie
Affiliations :
Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas.
Publications dans "Agonistes myélo-ablatifs" :
4 publications dans cette catégorie
Affiliations :
Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas.
Publications dans "Agonistes myélo-ablatifs" :
3 publications dans cette catégorie
Affiliations :
Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas.
Publications dans "Agonistes myélo-ablatifs" :
3 publications dans cette catégorie
Affiliations :
Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas.
Publications dans "Agonistes myélo-ablatifs" :
3 publications dans cette catégorie
Affiliations :
Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas.
Publications dans "Agonistes myélo-ablatifs" :
3 publications dans cette catégorie
Affiliations :
Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas.
Publications dans "Agonistes myélo-ablatifs" :
3 publications dans cette catégorie
Affiliations :
Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: upopat@mdanderson.org.
Publications dans "Agonistes myélo-ablatifs" :
3 publications dans cette catégorie
Affiliations :
King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia.
Publications dans "Agonistes myélo-ablatifs" :
3 publications dans cette catégorie
Affiliations :
Hôpital Universitaire Robert-Debré, Paris, France; Paediatric Disease Working Party of European Society for Blood and Marrow Transplantation.
Publications dans "Agonistes myélo-ablatifs" :
3 publications dans cette catégorie
Publications dans "Agonistes myélo-ablatifs" :
3 publications dans cette catégorie
Affiliations :
Division of Hematology/Oncology/Bone Marrow Transplantation, Department of Medicine, University of Wisconsin, Madison, Wisconsin, USA.
Publications dans "Agonistes myélo-ablatifs" :
3 publications dans cette catégorie
Affiliations :
Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
Publications dans "Agonistes myélo-ablatifs" :
3 publications dans cette catégorie
Affiliations :
Division of Hematology, Ohio State University, Columbus, Ohio, USA.
Publications dans "Agonistes myélo-ablatifs" :
3 publications dans cette catégorie
Affiliations :
Adult Bone Marrow Transplant Services, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
Publications dans "Agonistes myélo-ablatifs" :
3 publications dans cette catégorie
Affiliations :
Center for International Blood and Marrow Transplant Research, and.
Publications dans "Agonistes myélo-ablatifs" :
3 publications dans cette catégorie
Affiliations :
Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX.
Publications dans "Agonistes myélo-ablatifs" :
3 publications dans cette catégorie
Affiliations :
Division of Hematology/Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania.
Publications dans "Agonistes myélo-ablatifs" :
3 publications dans cette catégorie
Affiliations :
Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.
Publications dans "Agonistes myélo-ablatifs" :
3 publications dans cette catégorie
Affiliations :
Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
Publications dans "Agonistes myélo-ablatifs" :
3 publications dans cette catégorie
Affiliations :
Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
Publications dans "Agonistes myélo-ablatifs" :
Despite the high prevalence of alcohol use and binge drinking among older adults, little research has been conducted on the association between their alcohol risk perception and alcohol use patterns. ...
The correlates and consequences of stigma surrounding alcohol use are complex. Alcohol use disorder (AUD) is typically accompanied by self-stigma, due to numerous factors, such as shame, guilt and neg...
To investigate the relationship between self-stigma about alcohol dependence and the severity of alcohol consumption and craving....
In a sample of 64 participants, the majority of whom had a diagnosis of AUD (51), bivariate correlations were first conducted between Self-Stigma and Alcohol Dependence Scale (SSAD-Apply subscale) sco...
SSAD scores positively correlated with AUDIT scores, average drinks per drinking day, number of heavy drinking days and OCDS scores (p<0.001, p=0.014, p=0.011 and p<0.001, respectively). SSAD scores w...
Higher levels of self-stigma were associated with more severe AUD, greater alcohol consumption, and more obsessive thoughts and compulsive behaviours related to alcohol....
Our results suggest that potential interventions to reduce self-stigma may lead to improved quality of life and treatment outcomes for individuals with AUD....
We aimed to identify characteristics associated with alcohol drinking before and during pregnancy to better target pregnancy guidance and public health campaigns. A cross sectional study including 189...
To investigate the causal relationship between poor lifestyle habits, such as smoking and drinking, and cutaneous malignant melanoma....
In the present study, alcohol consumption and smoking were used as exposure factors, and single nucleotide polymorphisms closely associated with alcohol consumption and smoking were used as instrument...
We found a positive and statistically significant causal effect of alcohol intake on the risk of cutaneous malignant melanoma (OR: 2.23; 95%CI: 1.11-4.47; p=0.02). The present study showed no signific...
This study provides Mendelian randomization evidence supporting alcohol consumption as a risk factor for cutaneous malignant melanoma. And the causal relationship between smoking and cutaneous maligna...
In Australia, cask wine is the cheapest alcoholic beverage available, offering the lowest price per standard drink. Despite this, there is little research on the contextual correlates of cask wine con...
Cross-sectional data was drawn from two sources. Four waves of the National Drug Strategy Household Survey were used (2010, 2013, 2016 and 2019) in order to examine consumption trends over time. The I...
Cask wine was considerably cheaper than other forms of wine at $0.54 per standard drink (95% confidence interval [CI] 0.45-0.62, p < 0.05). Consumption trends associated with cask wine differed from t...
Cask wine drinkers are disproportionately more likely to consume higher amounts of alcohol, paying less per drink doing so compared to bottled wine drinkers. As all cask wine purchases were under $1.3...
Simultaneous alcohol and cannabis use (SAM) is associated with riskier drinking. However, little is known regarding mechanisms of risk during drinking episodes. The current study tested whether subjec...
Emerging adults who co-use alcohol and cannabis (N=85) completed 21 days of ecological momentary assessment with drink-contingent reports during drinking episodes. Participants reported on their simul...
At the momentary and day-level, SAM (vs. alcohol-only) use predicted increased high arousal positive/rewarding, low arousal positive/relaxing, and low arousal negative/impairing subjective effects. SA...
Simultaneous use was associated with reward, relief, and impairment, and reward and impairment were mechanisms of risk between SAM use and riskier drinking. Findings may inform theory and just-in-time...
In 2018, Scotland became the second country to implement minimum unit pricing (MUP) for all types of alcoholic beverages. The aim of this study was to examine the effect of the policy....
Three national household-level surveys were used: Scottish Health Surveys (2008-2021), Health Surveys in England (2011-2019), and Northern Ireland Continuous Household Survey (2011-2015). First, a gen...
Overall, drinking in Scotland began to decline prior to 2012 and dropped further with the enactment of MUP in 2018. In response to MUP, the likelihood of abstention increased along with a slight decre...
This study points to the impact of MUP in Scotland with a potential role for 'policy signalling' by the Scottish Government's with a multiple-buy discount ban and MUP's announcement since 2011-2012. I...
A mandatory pregnancy warning was introduced in Australia 2020 to advise the public of the potential harms of prenatal alcohol exposure. Due to industry pressure, a 3-year implementation period was gr...
The sample included 491 RTD products sold in three alcohol stores in Sydney, Australia in March-May 2022. Identified warnings were categorised as a mandated warning, a DrinkWise warning (an industry-d...
Almost all (94%) of the sampled RTD products had some form of pregnancy warning, but only 36% displayed the mandatory version. Of the non-mandatory warnings, 74% were DrinkWise warnings (42% of total ...
Two years into the three-year implementation period for the mandatory pregnancy warning, only around one-third of the assessed RTD products exhibited compliance. Uptake of the mandatory pregnancy warn...
Physical pain and negative emotions represent two distinct drinking motives that contribute to harmful alcohol use. Proactive avoidance, in contrast, can reduce consumption in response to these motive...
In recent years, women have significantly closed the alcohol use gender gap-and they are drinking more heavily now than in previous decades (Keyes et al., 2019). Furthermore, "wine-mom" culture (which...
Participants were mothers (M...
In the models tested, stress interacted with wine-mom-consistent drinking in predicting FAD (alcohol effects and restriction dimensions), and body dissatisfaction interacted with wine-mom-consistent d...
Wine-mom-consistent drinking is associated with problematic alcohol use and FAD among mothers. Further research is needed to better understand wine-mom culture and related psychosocial factors in moth...